Advertisement

Journal of Artificial Organs

, Volume 18, Issue 2, pp 120–127 | Cite as

Readmission due to driveline infection can be predicted by new score by using serum albumin and body mass index during long-term left ventricular assist device support

  • Teruhiko Imamura
  • Koichiro KinugawaEmail author
  • Daisuke Nitta
  • Toshiro Inaba
  • Hisataka Maki
  • Masaru Hatano
  • Osamu Kinoshita
  • Kan Nawata
  • Shunei Kyo
  • Minoru Ono
Original Article Artificial Heart (Clinical)

Abstract

Survival in patients with continuous flow left ventricular assist device (CF LVAD) had been increased owing to improved perioperative management procedures. The second target for successful long-term LVAD treatment was to reduce readmission especially due to device-specific infection, which was one of the major unsolved complications. Among 57 enrolled patients who had received CF LVAD and been followed for 530 days on median at our institute between 2008 and 2014, 21 patients experienced readmission due to driveline infection (DLI) at 190 days after the surgery on median. Considering the result of Uni/Multivariate Cox regression analyses demonstrating lower serum albumin concentration (S-ALB) (hazard ratio 0.144) and body mass index (BMI) (hazard ratio 0.843) both obtained at discharge were independent predictors of readmission due to DLI, we constructed a New Score “7 × [S-ALB (g/dL)] + [BMI]”, which significantly stratified readmission-free rate into 3 groups [low (>50 Pt), intermediate (44–50 Pt), and high risk group (<44 Pt)] during 2-year study period (p = 0.008). Survival remained unchanged irrespective of DLI, whereas those with DLI needed longer in-hospital treatment (p < 0.05). In conclusion, readmission due to DLI could be predicted by using two simple nutrition parameters at discharge. Early nutrition assessment and intervention may reduce readmission and improve patients’ quality of life during long-term LVAD support.

Keywords

Nutrition Cardiac cachexia Quality of life VAD 

Notes

Conflict of interest

None.

References

  1. 1.
    Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg. 2001;122:1186–95.PubMedGoogle Scholar
  2. 2.
    Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–43.PubMedGoogle Scholar
  3. 3.
    Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.PubMedGoogle Scholar
  4. 4.
    Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312–21.PubMedGoogle Scholar
  5. 5.
    Imamura T, Kinugawa K, Shiga T, et al. Novel risk scoring system with preoperative objective parameters gives a good prediction of 1-year mortality in patients with a left ventricular assist device. Circ J. 2012;76:1895–903.PubMedGoogle Scholar
  6. 6.
    Hannan MM, Husain S, Mattner F, et al. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant. 2011;30:375–84.PubMedGoogle Scholar
  7. 7.
    Zierer A, Melby SJ, Voeller RK, et al. Late-onset driveline infections: the Achilles’ heel of prolonged left ventricular assist device support. Ann Thorac Surg. 2007;84:515–20.PubMedGoogle Scholar
  8. 8.
    Holman WL, Naftel DC, Eckert CE, Kormos RL, Goldstein DJ, Kirklin JK. Durability of left ventricular assist devices: interagency registry for mechanically assisted circulatory support (INTERMACS) 2006–2011. J Thorac Cardiovasc Surg. 2013;146:437–41 e1.PubMedGoogle Scholar
  9. 9.
    Oz MC, Gelijns AC, Miller L, et al. Left ventricular assist devices as permanent heart failure therapy: the price of progress. Ann Surg. 2003;238:577–83 (discussion 83-5).PubMedCentralPubMedGoogle Scholar
  10. 10.
    Monkowski DH, Axelrod P, Fekete T, Hollander T, Furukawa S, Samuel R. Infections associated with ventricular assist devices: epidemiology and effect on prognosis after transplantation. Transpl Infect Dis. 2007;9:114–20.PubMedGoogle Scholar
  11. 11.
    Toda K, Yonemoto Y, Fujita T, et al. Risk analysis of bloodstream infection during long-term left ventricular assist device support. Ann Thorac Surg. 2012;94:1387–93.PubMedGoogle Scholar
  12. 12.
    Sharma V, Deo SV, Stulak JM, et al. Driveline infections in left ventricular assist devices: implications for destination therapy. Ann Thorac Surg. 2012;94:1381–6.PubMedGoogle Scholar
  13. 13.
    De Luis DA, Culebras JM, Aller R, Eiros-Bouza JM. Surgical infection and malnutrition. Nutr Hosp. 2014;30:509–13.PubMedGoogle Scholar
  14. 14.
    Goldstein DJ, Naftel D, Holman W, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant. 2012;31:1151–7.PubMedGoogle Scholar
  15. 15.
    Raymond AL, Kfoury AG, Bishop CJ, et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J. 2010;56:57–60.PubMedGoogle Scholar
  16. 16.
    Bomholt T, Moser C, Sander K, et al. Driveline infections in patients supported with a HeartMate II: incidence, aetiology and outcome. Scand Cardiovasc J. 2011;45:273–8.PubMedGoogle Scholar
  17. 17.
    Vega JD, Poindexter SM, Radovancevic B, et al. Nutritional assessment of patients with extended left ventricular assist device support. ASAIO Trans. 1990;36:M555–8.PubMedGoogle Scholar
  18. 18.
    Leeper B. Impact of obesity on care of postoperative coronary bypass patients. Crit Care Nurs Clin North Am. 2009;21:369–75 vi.PubMedGoogle Scholar
  19. 19.
    Martin SI, Wellington L, Stevenson KB, et al. Effect of body mass index and device type on infection in left ventricular assist device support beyond 30 days. Interact CardioVasc Thorac Surg. 2010;11:20–3.PubMedGoogle Scholar
  20. 20.
    Butler J, Howser R, Portner PM, Pierson RN 3rd. Body mass index and outcomes after left ventricular assist device placement. Ann Thorac Surg. 2005;79:66–73.PubMedGoogle Scholar
  21. 21.
    Coyle LA, Ising MS, Gallagher C, et al. Destination therapy: one-year outcomes in patients with a body mass index greater than 30. Artif Organs. 2010;34:93–7.PubMedGoogle Scholar
  22. 22.
    Arques S, Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. J Card Fail. 2011;17:451–8.PubMedGoogle Scholar
  23. 23.
    Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 1999;115:836–47.PubMedGoogle Scholar
  24. 24.
    Berry C, Clark AL. Catabolism in chronic heart failure. Eur Heart J. 2000;21:521–32.PubMedGoogle Scholar
  25. 25.
    Mano A, Fujita K, Uenomachi K, et al. Body mass index is a useful predictor of prognosis after left ventricular assist system implantation. J Heart Lung Transplant. 2009;28:428–33.PubMedGoogle Scholar
  26. 26.
    Kato TS, Kitada S, Yang J, et al. Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation. Am J Cardiol. 2013;112:1484–8.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Siegenthaler MP, Martin J, Pernice K, et al. The Jarvik 2000 is associated with less infections than the HeartMate left ventricular assist device. Eur J Cardiothorac Surg. 2003;23:748–54 (discussion 54–5).PubMedGoogle Scholar
  28. 28.
    Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg. 2010;90:1270–7.PubMedGoogle Scholar
  29. 29.
    Hieda M, Sata M, Seguchi O, et al. Importance of early appropriate intervention including antibiotics and wound care for device-related infection in patients with left ventricular assist device. Transplant Proc. 2014;46:907–10.PubMedGoogle Scholar
  30. 30.
    Nienaber JJ, Kusne S, Riaz T, et al. Clinical manifestations and management of left ventricular assist device-associated infections. Clin Infect Dis. 2013;57:1438–48.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Holdy K, Dembitsky W, Eaton LL, et al. Nutrition assessment and management of left ventricular assist device patients. J Heart Lung Transplant. 2005;24:1690–6.PubMedGoogle Scholar
  32. 32.
    Abicht T, Gordon R, Meehan K, Stosor V, McCarthy P, McGee E Jr. Complex HeartMate II infection treated with pump exchange to HeartWare HVAD. ASAIO J. 2013;59:188–92.PubMedGoogle Scholar
  33. 33.
    Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato EF. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980;139:160–7.PubMedGoogle Scholar
  34. 34.
    Aggarwal A, Kumar A, Gregory MP, et al. Nutrition assessment in advanced heart failure patients evaluated for ventricular assist devices or cardiac transplantation. Nutr Clin Pract. 2013;28:112–9.PubMedGoogle Scholar

Copyright information

© The Japanese Society for Artificial Organs 2015

Authors and Affiliations

  • Teruhiko Imamura
    • 1
  • Koichiro Kinugawa
    • 1
    Email author
  • Daisuke Nitta
    • 2
  • Toshiro Inaba
    • 2
  • Hisataka Maki
    • 2
  • Masaru Hatano
    • 2
  • Osamu Kinoshita
    • 3
  • Kan Nawata
    • 3
  • Shunei Kyo
    • 1
  • Minoru Ono
    • 3
  1. 1.Department of Therapeutic Strategy for Heart Failure, Graduate School of MedicineUniversity of TokyoTokyoJapan
  2. 2.Department of Cardiovascular MedicineUniversity of TokyoTokyoJapan
  3. 3.Department of Cardiac Surgery, Graduate School of MedicineUniversity of TokyoTokyoJapan

Personalised recommendations